Coronaviruses (CoV), discovered after 1960, caused human life-threatening outbreaks. SARS-CoV2, which appeared in Wuhan, China in December 2019, causing Severe Acute Respiratory Syndrome and has different features than other coronaviruses, has been determined and the disease caused by the virus has been called “Coronavirus Disease-2019” (COVID-19). This disease activates both the natural and acquired immune system. The cytokin storm, in which blood levels of proinflammatory cytokines are detected excessively high is developing and the uncontrolled inflammatory response causes local and systemic tissue damages. Although a spesific drug has not been found yet, the medications currently in use for other indications, whose pharmacokinetic- pharmacodynamic properties and toxic doses are already known; are included in the treatment practice of COVID-19. These drugs affect the entry of the virus into the cell and its intracellular distribution. They also have anti-inflammatory and immunomodulating effects too. Therefore, we think that Proton Pump Inhibitors (PPI’s) with similar mechanisms of action may also be involved in COVID-19 treatment and prophylaxis.

Coronavirus ) is a disease that started at the end of 2019 and continues to affect all the world as a pandemic. There is no definitive cure for COVID-19 yet. The disease is characterized by excessive immune activity, inflammation and coagulopathy. Many agents have been tried for treatment and prevention. Flavonoids are valuable natural food components with antioxidant, anti-inflammatory and anticoagulant properties. Quercetin, the best known flavonoid, is one of the most studied and beneficial one. Quercetin, which has been shown to be effective in many viral diseases, is mainly used in diseases such as cardiovascular disease and diabetes, which are associated with chronic inflammation. it is an important candidate for the treatment and prophylaxis of COVID-19, thanks to its powerful anti-inflammatory, antioxidant and immune-modulating effects.

Colorectal cancer is the third most lethal and fourth most commonly diagnosed cancer worldwide. Sinapic acid, a derivative of hydroxycinnamic acid, is a promising phytochemical exhibiting numerous pharmacological activities in various systems. It is a substantial chain-breaking antioxidant that operates as a radical scavenger. The aim of this research was to investigate the antiproliferative effect of sinapic acid on the HT-29 cell line, besides the mechanisms underlying this activity. The effect of sinapic acid on the viability of HT-29 cell line was investigated using XTT assay. the levels of BCL-2, cleaved caspase 3, BAX, cleaved PARP and 8-oxo-dG were measured using ELISA. Gamma-H2AX and cytochrome C expression was assessed semi-quantitatively using immunofluorescence staining. Sinapic acid at 200 μM and higher doses produced a significant antiproliferative effect on HT-29 cells. The IC50 value was found to be 317.5 μM for 24 hours. Sinapic acid (317.5 μM) significantly elevated cleaved caspase 3, BAX, cleaved PARP and 8-oxo-dG levels. the levels of γ-H2AX foci are significantly higher while the levels of cytochrome-C are lower in sinapic acid treated HT-29 cells. These results indicate that sinapic acid has an antiproliferative, apoptotic and genotoxic effect on colon cancer cells.

No abstract

No abstract